News

KeyCorp Financial Review: Insights After 3Q Earnings Update

KeyCorp Financial Review: Insights After 3Q Earnings Update

KeyCorp's Earnings Performance Overview

Goldman Sachs recently reaffirmed its Buy rating on KeyCorp (NYSE: KEY) and set a stock price target at $19.00, following the release of the company’s third-quarter earnings report. In this report, KeyCorp disclosed an earnings per share (EPS) of ($0.47). When accounting for various one-time expenses such as a $918 million securities adjustment and a $6 million FDIC reversal, the core EPS is estimated to be $0.30. This figure slightly surpasses the consensus prediction of $0.28, attributed largely to lower operational costs.

Financial Highlights

KeyCorp’s core pre-provision net revenue (PPNR) stood out in the latest quarter, outperforming projections with a reported figure of $513 million compared to the anticipated $496 million. This positive performance was buoyed by a reduction in expenses as well as an improvement in net interest income (NII), which climbed to $952 million against the consensus estimate of $938 million. Despite some setbacks in core fee income, which totaled $649 million, slightly falling short of the $664 million expectation, the overall financial outlook remained robust.

Net Interest Margins and Loan Yields

The net interest margin (NIM) for KeyCorp was reported at 2.17%, marginally below the expected 2.20%. On the deposits front, the average deposits grew by 2.5% to reach $147.77 billion, exceeding forecasts by 1.9%. The demand deposit account (DDA) deposits experienced a modest quarter-over-quarter increase of 0.9%, resulting in a higher-than-expected deposit mix of 20.2% as opposed to the forecast of 19.1%.

Loan and Securities Insights

Regarding loan and securities yields, KeyCorp experienced a rise in loan yields by 7 basis points quarter-over-quarter, reaching 5.73%, which aligned with expectations. Securities yields also saw a rise, going up by 45 basis points to 2.87%, although this fell short of the anticipated 3.07% due to adjustments in the securities portfolio. The interest-bearing deposit costs rose by 11 basis points quarter-over-quarter to 2.96%, which was higher than the expected 2.88%.

Credit Losses and Loan Quality

A key metric of credit health, the provision for credit losses, came in lower than anticipated at $95 million, compared to the $104 million consensus. Nonetheless, net charge-offs were higher than expected at approximately 0.58 basis points against an anticipated 38 basis points. Despite this, the total criticized loans showed a 2% decrease while nonperforming loans (NPLs) rose by 2.5%, now sitting at 0.69%.

Capital Position and Future Guidance

KeyCorp's tangible book value per share (TBVPS) reflected a healthy increase of 15.8%, now at $11.72. The common equity Tier 1 (CET1) capital grew by 30 basis points to 10.8%, while adjusted CET1 capital experienced a significant jump of approximately 90 basis points quarter-over-quarter to around 8.6%.

As for future expectations, KeyCorp updated its full-year 2024 guidance, indicating a potential decrease in average loans while anticipating higher fees and expenses. The company reiterated its net interest income forecast while adjusting net charge-off expectations to the higher end of the previously estimated range.

Market Reactions and Analyst Perspectives

Analysts such as those at Barclays noted that KeyCorp’s EPS has exceeded expectations, maintaining an Equalweight rating with a $16 price target. On the other hand, Baird downgraded their view from Outperform to Neutral, reducing the price target to $17, citing a significant surge in the stock’s value.

Investment Adjustments

Recently, KeyCorp sold about $7 billion worth of low-yielding investment securities, which is projected to result in an after-tax loss of about $700 million for the third quarter of 2024. Despite adverse effects from this transaction, the company has lifted its 2024 fee income projections.

Future Financial Projections

Analysts from firms like Piper Sandler and Citi expressed optimism regarding KeyCorp’s future. Citi recently raised its EPS forecast for 2025 to $1.55, while Piper Sandler upheld an Overweight rating on the stock. Additionally, Jefferies has raised its price target for KeyCorp shares to $19.00, indicating sustained confidence in the bank's financial outlook.

Frequently Asked Questions

What is KeyCorp's current EPS?

KeyCorp's current EPS stands at ($0.47), although adjusted for one-time expenses, the core EPS is estimated at $0.30.

What are the primary challenges KeyCorp faces?

The main challenges include lower core fees and higher-than-expected net charge-offs, although PPNR has exceeded forecasts.

How has KeyCorp's tangible book value changed?

KeyCorp's tangible book value per share has increased by 15.8% to $11.72.

What ratings are analysts giving KeyCorp?

Analysts have mixed views, with Barclays maintaining an Equalweight rating and Baird downgrading to Neutral.

What is the outlook for KeyCorp's 2024 guidance?

KeyCorp projected a decline in average loans, with adjustments made to both net charge-off expectations and fee income guidance.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

GEEKOM A5 2027: Mini PC Built to Boost Your Game

Updated Category News Views 1

GEEKOM Raises the Bar with A5 2027 Build Every once in a blue moon, a piece of tech pricks up my ears and this time it's the GEEKOM A5 2027 Edition. Released on September 7, 2026, this contraption's not just joining the ranks—it's looking to redefine them. It's geared for the real-world junkie who’s raking through browser tabs, dropping into video meetings, and making...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 4

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Lab Glassware Market Set for Steady Growth by 2031

Updated Category News Views 1

When you dive into the world of laboratory glassware, it might look like it's all pipettes and test tubes, but there's more bubbling under the surface. This market's got its eyes on a neat little climb from $7,630 million in 2026 to a forecasted $9,170 million by 2031. Ain't just speculation—this one's solid muscle growing at a comfortable 4.0% compound annual growth...

Continue Reading
CalExitNow Fights Federal Interference in CA Elections

Updated Category News Views 2

California's Election Integrity: A Ticking Time Bomb Strap in for a bumpy ride, folks—California might soon find its electoral process caught in a Washington whirlwind. CalExitNow, the group advocating for California's independence, is sounding alarms about looming federal interventions that could shake the state's democratic foundations. The Federal Storm Rolling In...

Continue Reading
Universal Music Wraps €250M Share Buyback Plan

Updated Category News Views 1

Universal's Encore Performance in the Markets Universal Music Group (EURONEXT: UMG), the behemoth in music-based entertainment, just wrapped up its €250 million share buyback program. Talk about a grand finale! In a week’s worth of maneuvering from August 31 to September 4, they snagged 294,340 of their own shares, all for the pretty price of €14.65 a pop. Grand...

Continue Reading
Ping An Climbs Sustainability Ladder, Scores A+ Rating

Updated Category News Views 4

Sustainability Triumph for Ping An: A+ Upgrade Ping An Insurance (Group) Company of China, Ltd. is having quite the moment, snagging an A+ in the latest 2026 Sustainability Rating from Hang Seng Indexes Company. This ain't just a one-time pat on the back—it's the third year of consecutive improvement. Looks like Ping An's focus on ESG efforts is finally getting the...

Continue Reading
Withings and FFBB Team Up for Healthier Hoops

Updated Category News Views 3

Withings Joins Forces with French Basketball Elite When it comes to linking technology and sports, nothing quite shows promise like Withings teaming up with the French Basketball Federation (FFBB). Picture this: a French startup that's crafted its legacy on cutting-edge health tech now throws its lot in with a nation proud of its basketball prowess. It's the kind of...

Continue Reading
Regan Hutsell Shines as 99th Miss America Winner

Updated Category News Views 0

There's a buzz in the air that's hard to ignore—Regan Hutsell from Texas secured the legendary Miss America crown. This event isn't just another chapter in the pageant's nearly century-old saga, but it's a spotlight moment that nods to Miss America's long-enduring cultural resonance. Now, you might be wondering: With all eyes on this Texan, what ripples could she send...

Continue Reading
TECNO CAMON Slim 5G: Where Art Meets Tech

Updated Category News Views 1

Unveiling the TECNO CAMON Slim 5G Okay, so imagine a tech brand saying, 'Why not make a phone that’s as much an art piece as it is a gadget?' TECNO just pulled this off with their latest CAMON Slim 5G. The thing's a sleek marvel measuring in at just 6.39mm. Seems like they took a fat-free diet approach to phone design, and not on the digital calories either. A Slim Body...

Continue Reading

Top 5 Most Recently Viewed Articles

Tevogen Bio Advocates for Long COVID Solutions on Capitol Hill

Updated Category News Views 70

Tevogen Bio Champions Long COVID Patient Advocacy Tevogen Bio, a clinical-stage biotech company specializing in immunotherapy, is drawing attention for its proactive stance on important healthcare challenges. Recently, the company has turned its focus to advocating for patients with Long COVID. This initiative gained prominence when Tevogen's leadership met with members...

Continue Reading
Rybelsus® Shows Promising Cardiovascular Benefits in SOUL Trial

Updated Category News Views 515

Rybelsus® Shows Significant Reduction in Cardiovascular Events Recent findings from the SOUL cardiovascular outcomes trial have highlighted the effectiveness of Rybelsus® (oral semaglutide) in significantly reducing the risk of major adverse cardiovascular events (MACE) among adults suffering from type 2 diabetes and associated conditions. Clinical data from the trial...

Continue Reading
Quipt Home Medical Reports Promising Q1 Fiscal 2025 Results

Updated Category News Views 312

Quipt Home Medical's Strong Start to Fiscal Year 2025 Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT), a prominent provider of home medical equipment with a focus on respiratory care, shared its financial results for the first quarter of fiscal year 2025, covering the three-month period ending December 31, 2024. Diligently reported in U.S. Dollars, these results...

Continue Reading
Argent BioPharma Secures $4.5 Million in Capital Raise

Updated Category News Views 147

Argent BioPharma's Successful Capital Raise and Future Prospects Argent BioPharma Limited (ASX: RGT) is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for central nervous system (CNS) and immune-related disorders through advanced nano-medicine technology and neuro-immune modulation. Recently, Argent BioPharma announced a...

Continue Reading
Bernie Sanders Highlights High Costs of Ozempic and Patient Impact

Updated Category News Views 56

Bernie Sanders Criticizes High Costs of Ozempic Senator Bernie Sanders has recently expressed his deep frustration over the soaring prices of Ozempic, a medication made by Novo Nordisk A/S (NYSE: NVO). While it’s primarily prescribed for managing diabetes, Ozempic has also become popular as a weight loss solution. Inconsistent Medication Prices In a fervent post on...

Continue Reading